Co-Expression of Stem Cell and Epithelial Mesenchymal Transition Markers in Circulating Tumor Cells of Bladder Cancer Patients

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Oct 30

PMID 33122913

Citations 11

Authors

Ruiyun Zhang

Jun Xia

Yiqiu Wang

Ming Cao

Di Jin

Wei Xue

Yiran Huang

Haige Chen

Affiliations

Soon will be listed here.

Abstract

Objective: Cancer cells with stemness and epithelial-to-mesenchymal transition (EMT) features display enhanced malignant and metastatic potential. This study aimed to introduce a new methodology developed in order to investigate the co-expression of a stemness (OCT4) and EMT markers on single circulating tumor cells (CTCs) of patients with localized urinary bladder cancer and their potential prognostic prediction value.

Methods And Materials: Between April 2015 and July 2015, blood samples of 51 consecutive patients diagnosed with high risk bladder cancer (cTNM) were prospectively investigated for CTCs. Peripheral blood (5 mL) was drawn before primary transurethral resection. Detection of CTCs was performed using the CanPatrol system. Nucleic acid probes were used to identify CTCs, and expression levels of epithelial and mesenchymal genes in CTCs were examined by situ hybridization assay.

Results: All patients received radical cystectomy with pelvic lymph nodes dissection. CTCs were detected in 44 of 51 (86.3%) patients, respectively. The overall mean number of CTCs was 6.1 (range: 0~29; median: 4). A total of 311 CTCs were detected in PB. High OCT4 expression (OCT4) was detected more frequently in EpiMes cells (p=0.001). Patients with pathological confirmed muscle-invasive bladder cancer (MIBC) had higher EpiMes CTCs positive rates (p=0.001) and OCT4 CTCs positive rates (p=0.019) than pathological confirmed non muscle-invasive bladder cancer (NMIBC). Regarding co-expression of these markers, EpiMes/OCT4 CTCs were more frequently evident in the MIBC setting (30.4% vs 3.6% of patients, p = 0.016).

Conclusion: A differential expression pattern for these markers was observed both in NMIBC and MIBC disease. A subgroup of CTCs showed a CTCs expressing high OCT4, along with Mes were more frequently detected in patients with MIBC, suggesting that these cells may prevail during tumor muscle invasion and disease progression.

Citing Articles

Current biological implications and clinical relevance of metastatic circulating tumor cells.

Shahhosseini R, Pakmehr S, Elhami A, Shakir M, Alzahrani A, Al-Hamdani M Clin Exp Med. 2024; 25(1):7.

PMID: 39546080 PMC: 11567993. DOI: 10.1007/s10238-024-01518-6.

Metastases and treatment-resistant lineages in patient-derived cancer cells of colorectal cancer.

Fujino S, Miyoshi N, Ito A, Hayashi R, Yasui M, Matsuda C Commun Biol. 2023; 6(1):1191.

PMID: 37996567 PMC: 10667365. DOI: 10.1038/s42003-023-05562-y.

OCT4‑positive circulating tumor cells may predict a poor prognosis in patients with metastatic castration‑resistant prostate cancer treated with abiraterone plus prednisone therapy.

Ma Y Oncol Lett. 2023; 26(4):452.

PMID: 37720669 PMC: 10502952. DOI: 10.3892/ol.2023.14039.

Cancer stem cells: an insight into the development of metastatic tumors and therapy resistance.

Nairuz T, Mahmud Z, Manik R, Kabir Y Stem Cell Rev Rep. 2023; 19(6):1577-1595.

PMID: 37129728 DOI: 10.1007/s12015-023-10529-x.

Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer.

Li S, Xin K, Pan S, Wang Y, Zheng J, Li Z Cell Mol Biol Lett. 2023; 28(1):28.

PMID: 37016296 PMC: 10074703. DOI: 10.1186/s11658-023-00442-z.

References

Liberko M, Kolostova K, Bobek V . Essentials of circulating tumor cells for clinical research and practice. Crit Rev Oncol Hematol. 2013; 88(2):338-56. DOI: 10.1016/j.critrevonc.2013.05.002. View

Visvader J . Cells of origin in cancer. Nature. 2011; 469(7330):314-22. DOI: 10.1038/nature09781. View

Alva A, Friedlander T, Clark M, Huebner T, Daignault S, Hussain M . Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. J Urol. 2015; 194(3):790-8. PMC: 5103704. DOI: 10.1016/j.juro.2015.02.2951. View

Hollier B, Evans K, Mani S . The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia. 2009; 14(1):29-43. DOI: 10.1007/s10911-009-9110-3. View

Nezos A, Pissimisis N, Lembessis P, Sourla A, Dimopoulos P, Dimopoulos T . Detection of circulating tumor cells in bladder cancer patients. Cancer Treat Rev. 2008; 35(3):272-9. DOI: 10.1016/j.ctrv.2008.11.003. View

Dancik G, Owens C, Iczkowski K, Theodorescu D . A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells. 2013; 32(4):974-82. PMC: 3960367. DOI: 10.1002/stem.1625. View

Yu W, Kamara H, Svoboda K . The role of twist during palate development. Dev Dyn. 2008; 237(10):2716-25. DOI: 10.1002/dvdy.21627. View

Paterlini-Brechot P, Benali N . Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007; 253(2):180-204. DOI: 10.1016/j.canlet.2006.12.014. View

Chaffer C, Brennan J, Slavin J, Blick T, Thompson E, Williams E . Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006; 66(23):11271-8. DOI: 10.1158/0008-5472.CAN-06-2044. View

10.

Giuliano M, Giordano A, Jackson S, Hess K, De Giorgi U, Mego M . Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011; 13(3):R67. PMC: 3218956. DOI: 10.1186/bcr2907. View

11.

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

12.

Larsson A, Wilhelmsson U, Pekna M, Pekny M . Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP(-/-)Vim(-/-) mice. Neurochem Res. 2005; 29(11):2069-73. DOI: 10.1007/s11064-004-6880-2. View

13.

Chan K, Espinosa I, Chao M, Wong D, Ailles L, Diehn M . Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009; 106(33):14016-21. PMC: 2720852. DOI: 10.1073/pnas.0906549106. View

14.

Leotsakos I, Dimopoulos P, Gkioka E, Msaouel P, Nezos A, Stravodimos K . Detection of circulating tumor cells in bladder cancer using multiplex PCR assays. Anticancer Res. 2014; 34(12):7415-24. View

15.

Polyak K, Weinberg R . Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4):265-73. DOI: 10.1038/nrc2620. View

16.

Kiselyov A, Bunimovich-Mendrazitsky S, Startsev V . Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment. Int J Cancer. 2015; 138(11):2562-9. DOI: 10.1002/ijc.29918. View

17.

Jozwicki W, Brozyna A, Siekiera J . Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression. Int J Mol Sci. 2014; 15(9):16069-82. PMC: 4200762. DOI: 10.3390/ijms150916069. View

18.

Liu Y, Hu B, Li Z, He X, Li Y, Lu L . An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients. Hepatol Int. 2016; 10(4):640-6. DOI: 10.1007/s12072-016-9732-7. View

19.

Kenney P, Wszolek M, Rieger-Christ K, Silva Neto B, Gould J, Harty N . Novel ZEB1 expression in bladder tumorigenesis. BJU Int. 2010; 107(4):656-63. DOI: 10.1111/j.1464-410X.2010.09489.x. View

20.

Lu C, Shieh G, Wang C, Su B, Su Y, Chen Y . Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer. Oncotarget. 2016; 8(19):30844-30858. PMC: 5458172. DOI: 10.18632/oncotarget.9602. View